October 11, 2026
Good morning, everyone. I grabbed my espresso, sat at that usual table, and I'll say it upfront: the market today has two engines running at the same time, one of euphoria and one of fear. On one side, the cancer vaccine frenzy pushing biotech to bubble levels; on the other, missiles in the Middle East and a climate case at the U.S. Supreme Court that could shake the entire energy sector. Let's get to what matters.
The fact: Cancer vaccine-related stocks (MRNA, BNTX, NVAX) soared after reports that the U.S. NIH will make a heavy bet on the sector, and Moderna has already gained over 500% this year, trading 61% above Wall Street's average price target.
My verdict: I Would Sell (at least part of the position). When a stock trades 60% above analyst consensus and the key result still depends on unpublished detailed data, you're not investing — you're gambling. I'd rather lock in profit than dance with the market until the music stops.
Assets and sectors on the radar:
MRNA (Moderna) — I would sell partiallyBNTX (BioNTech) — I would only hold if you have a strong stomachNVAX (Novavax) — I would trim, it's the weakest in the groupThe fact: Scientists are advancing in the creation of genetically modified cells that hunt tumors, consolidating CAR-T as one of the most promising — and expensive — avenues of modern oncology.
My verdict: I Would Buy exposure to the theme via big pharma companies that already have a CAR-T pipeline. It's not a short-term trade, it's a multi-year position. The risk is high, but so is the reward.
Assets and sectors on the radar:
JNJ, PFE) — I would buyThe fact: JPMorgan's asset management arm made an openly optimistic bet on high-quality fixed income, calling the opportunity "once in a generation" after years of poor allocation in that market.
My verdict: I Would Buy. When a giant of that size sends that kind of signal, it's usually because spreads are attractive and the risk-reward has improved without retail investors noticing. It's that "boring trade that makes money."
Assets and sectors on the radar:
LQD) — I would buyIEF) — I would buyThe fact: Riyadh airport was evacuated and shut down after a missile attack attributed to Yemen's Houthis, escalating regional instability.
My verdict: I Would Reduce exposure to cyclical assets and airlines with heavy Middle East routes. Geopolitics in the Gulf is one of those things nobody prices in properly until the day it prices everything in at once.
Assets and sectors on the radar:
Brent, WTI) — I would buy as a hedgeLUV, DAL with indirect exposure) — I would reduceLMT, RTX) — I would holdThe fact: The Russia-Ukraine war has extended to the Black Sea, and grain prices have already risen 18% year over year, according to the FAO, with the risk of a global food crisis.
My verdict: I Would Buy exposure to agricultural commodities as protection and as a thesis. Food inflation is a theme that comes back with force when export routes are threatened — and that tends to spill over into emerging markets and consumers.
Assets and sectors on the radar:
DBA, WEAT) — I would buyMOS, NTR) — I would hold with an upward biasThe fact: Experts warn that the climate case Suncor v. Boulder at the U.S. Supreme Court could open thousands of climate liability lawsuits, potentially bankrupting oil companies and driving up gasoline prices.
My verdict: I Would Red
Ivar recommends Swissquote bank for your international investments. By opening your account through the link below and trading 5 lots or more, you will receive $200 to use on Ivar AI and activate your subscription. Take advantage of this exclusive offer available today!
Offer available for you who have not yet opened your account at Swissquote.
Services available globally except for the following countries: Algeria, Belgium, Canada, China, North Korea, USA, France, Hong Kong, Iran, Iraq, Nigeria, Singapore, Syria, Turkey and Zimbabwe.